Table 2.
Comparators Between the Pregnant Patients and Control Subjects
| Pregnant Cohort (n = 17) | Nonpregnant Females (n = 247) | P | |
|---|---|---|---|
| Age, median (range), y | 35 (25–52) | 44 (17–52) | Not calculated |
| No. with sporadic disease, MEN, or familial | 16 sporadic, 1 MEN1 | 229 sporadic, 15 MEN, 3 familial | 0.82 |
| Preoperative serum corr Ca, median, mmol/L | 2.89 (2.56–3.3) | 2.78 (2.35–3.54) | 0.03a |
| Preoperative serum PTH, median, pmol/L | 15.9 (6–32) | 18 (4.5–138) | 0.40 |
| USS localization positive, no. (%) | 8 (47) | 84 (34) | 0.36 |
| Sestamibi scan, positive, no. (%) | 2/6 (33) | 104 (42) | 0.59 |
| Type of operation, no. (%) | 0.22 | ||
| Bilateral exploration | 13 (87) | 178 (72) | |
| Targeted approach | 2 (13) | 69 (28) | |
| Pathology, no. (%) | 0.55 | ||
| Single adenoma | 11 (73) | 197 (80) | |
| Multigland disease | 4 (27) | 50 (20) | |
| Outcome | 17 cured, 0 persistent disease,b 1 recurrence | 237 cured, 10 persistent hypercalcemia (4%), 0 recurrences |
Abbreviations: Corr, corrected, i.e. albumin-corrected; MEN, multiple endocrine neoplasia; MEN1, multiple endocrine neoplasia type 1; USS, ultrasound scan.
a
Significant at P < 0.05.
b
Defined as failure to maintain serum calcium and PTH levels within normal limits during the 12 months postoperatively and recurrence as a normalization of biochemistry in the first 12 months, followed by elevated calcium or PTH levels thereafter.